drugset / Trial / NCT02224157

A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma

NCT02224157

Phase 3 Completed 4215 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to test if Symbicort (budesonide/formoterol) Turbuhaler is effective in treating asthma when used 'as needed' in patients with milder asthma. The efficacy of Symbicort 'as needed' will be compared with Pulmicort (budesonide) Turbuhaler twice daily plus terbutaline Turbuhaler 'as needed'

Timeline

Start
2014-11-28
Primary completion
2017-08-16
Completion
2017-08-16

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 160 ug Inhaled
Comparator Budesonide Small molecule 200 ug Inhaled
Subject Formoterol Other / unclassified 4.5 ug Inhaled
Comparator Terbutaline Small molecule 0.4 mg Inhaled

Indications